Problems of Cancer Treatment. Part I. Theory of Treatment Based on Known Mechanisms of Anticancer Immunological Responses

Open access

Summary

Various processes, taking place both in cells and in their environment, are linked to carcinogenesis. This paper aims at recalling the complex mechanisms of oncogenesis, with particular attention paid to responses of the immune system. In development of solid tumours, leukaemias and lymphomas several common stages can be noted. A neoplastic disease cannot be understood considering only phenomena of genetic mutations. Neoplastic cells are characterised by an extensive antigenic variability and resistance to apoptosis. The cells create around them a microenvironment which protects them from defensive activity of the host. In the paper we present the recognised mechanisms of anti-neoplastic defense as well as several elements allowing the solid tumours and leukaemias to escape from the immune surveillance. The generally accepted treatment of tumours aims at reducing numbers of tumour cells. Following resection of a tumour, radiotherapy or chemotherapy, the parallel or consecutive stage of treatment was found to involve an increase in number of clones of immune system cells. One of the ways in which the immune system can be activated involves autovaccination of the host with own neoplastic cells in an apoptosis. However, attempts of such a therapy frequently brought no expected results due to blocked activity of cytotoxic cells. Therefore, the subsequent stage in activation of the immune system should involve elimination of the tumor-mobilized blockade of the system. Attempts toward this aim include neutralization of the tumour-blocked cytotoxic properties of defensive cells, first of all T lymphocytes. The recognized mechanisms of blocking T cells activity in the PD-1/PD-L1 system or due to inhibition of activation by CTLA-4 molecule provided rationale for development of effective tumour immunotherapy approaches.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • [1] Aerts JG Hegmans JP. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res 2013; 73(8): 2381-2388.

  • [2] Amarante-Mendes GP Griffith TS. Therapeutic applications of TRAIL receptor agonists in cancer and beyond. Pharmacol Ther 2015 155: 117-31.

  • [3] Arvelo F Sojo F Cotte C. Biology of colorectal cancer. Ecancermedicalscience 2015; 9:520.

  • [4] Berman D Korman A Peck R Feltquate D Lonberg N Canetta R. The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience. Pharmacol Ther 2015; 148: 132-153.

  • [5] Bologna L Gotti E Da RF Intermesoli T Rambaldi A Introna M et al. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J Immunol 2013; 190(1): 231-239.

  • [6] Bologna L Gotti E Manganini M Rambaldi A Intermesoli T Introna M et al. Mechanism of action of type II glycoengineered anti-CD20 monoclonal antibody GA101 in B-chronic lympho cytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011; 186(6): 3762-3769.

  • [7] Bolton-Gillespie E Schemionek M Klein HU Flis S Hoser G Lange T et al. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood 2013; 121(20): 4175-4183.

  • [8] Brandhorst G Petrova DT Weigand S Eberle C von AN Schmitz J et al. Lack of correlation between Treg quantification assays in inflammatory bowel disease patients. World J Gastroenterol 2015; 21(11): 3325-3329.

  • [9] Burkholder B Huang RY Burgess R Luo S Jones VS Zhang W et al. Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta 2014; 1845(2): 182-201.

  • [10] Calpe E Purroy N Carpio C Abrisqueta P Carabia J Palacio C et al. ZAP-70 promotes the infiltration of malignant B-lymphocytes into the bone marrow by enhancing signaling and migration after CXCR4 stimulation. PLoS One 2013; 8(12): e81221.

  • [11] Capelletto E Novello S Scagliotti GV. First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era. Future Oncol 2014; 10(6): 1081-1093.

  • [12] Caramalho I Nunes-Cabaco H Foxall RB Sousa AE. Regulatory T-Cell Development in the Human Thymus. Front Immunol 2015; 6: 395.

  • [13] Martins VC Busch K Juraeva D Blum C Ludwig C Rasche V Lasitschka F Mastitsky SE Brors B Hielscher T Fehling HJ Rodewald HR. Cell competition is a tumour suppressor mechanism in the thymus. Nature. 2014 May22; 509(7501): 465-70.

  • [14] Carbognin L Pilotto S Milella M Vaccaro V Brunelli M Calio A et al. Differential Activity of Nivolumab Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma Lung and Genitourinary Cancers. PLoS One 2015; 10(6) :e0130142.

  • [15] Catusse J Leick M Groch M Clark DJ Buchner MV Zirlik K et al. Role of the atypical chemoattractant receptor CRAM in regulating CCL19 induced CCR7 responses in B-cell chronic lymphocytic leukemia. Mol Cancer 2010; 9: 297.

  • [16] Chen L Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013; 13(4): 227-242.

  • [17] Colussi D Brandi G Bazzoli F Ricciardiello L. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 2013; 14(8): 16365-16385.

  • [18] Crassini K Mulligan SP Best OG. Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date. World J Clin Cases 2015; 3(8): 694-704.

  • [19] Dabrowska M Grubek-Jaworska H Hoser G Domagala-Kulawik J Krenke R Chazan R. Effect of IFN-gamma stimulation on expression of intercellular adhesion molecule-1 (ICAM-1) on alveolar macrophages in patients with non-small cell lung cancer. J Interferon Cytokine Res 2006; 26(3): 190-195.

  • [20] Danilov AV Soderquist RS Bates DJ Eastman A. Toward a cure for chronic lymphocytic leukemia: an attack on multiple fronts. Expert Rev Anticancer Ther 2013; 13(9): 1009-1012.

  • [21] Didkowska J Manczuk M McNeill A Powles J Zatonski W. Lung cancer mortality at ages 35-54 in the European Union: ecological study of evolving tobacco epidemics. BMJ 2005; 331(7510): 189-191.

  • [22] Dillon PM Olson WC Czarkowski A Petroni GR Smolkin M Grosh WW et al. A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes. J Immunother Cancer 2014; 2: 23.

  • [23] Domagala-Kulawik J. Effects of cigarette smoke on the lung and systemic immunity. J Physiol Pharmacol 2008; 59 Suppl 6: 19-34.

  • [24] Domagala-Kulawik J Guzman J Costabel U. Immune cells in bronchoalveolar lavage in peripheral lung cancer--analysis of 140 cases. Respiration 2003; 70(1): 43-48.

  • [25] Domagala-Kulawik J Hoser G Dabrowska M Chazan R. Increased proportion of Fas positive CD8+ cells in peripheral blood of patients with COPD. Respir Med 2007; 101(6): 1338-1343.

  • [26] Domagala-Kulawik J Hoser G Droszcz P Kawiak J Droszcz W Chazan R. T-cell subtypes in bronchoalveolar lavage fluid and in peripheral blood from patients with primary lung cancer. Diagn Cytopathol 2001; 25(4): 208-213.

  • [27] Domagala-Kulawik J Osinska I. (Immune alterations in lung cancer - the new therapeutic approach). Pneumonol Alergol Pol 2014; 82(3): 286-299.

  • [28] Domagala-Kulawik J Osinska I Hoser G. Mechanisms of immune response regulation in lung cancer. Transl Lung Cancer Res 2014; 3(1): 15-22.

  • [29] Donnem T Hald SM Paulsen EE Richardsen E Al-Saad S Kilvaer TK et al. Stromal CD8+ T-cell Density-A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer. Clin Cancer Res 2015; 21(11): 2635-2643.

  • [30] Dummer CD Carpio VN Goncalves LF Manfro RC Veronese FV. FOXP3+ regulatory T cells: from suppression of rejection to induction of renal allograft tolerance. Transpl Immunol 2012; 26(1): 1-10.

  • [31] Dunn GP Bruce AT Ikeda H Old LJ Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3(11): 991-998.

  • [32] ERS. European Lung White Book. ERS ed. 2014.

  • [33] Fossati V Kumar R Snoeck HW. Progenitor cell origin plays a role in fate choices of mature B cells. J Immunol 2010; 184(3): 1251-1260.

  • [34] Franceschi C Bonafe M Valensin S Olivieri F De LM Ottaviani E et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000; 908: 244-254.

  • [35] Frydecka I Kosmaczewska A Bocko D Ciszak L Wolowiec D Kuliczkowski K et al. Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukaemia. Br J Cancer 2004; 90(10): 2042-2048.

  • [36] Fulda S Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25(34): 4798-4811.

  • [37] Fulop T Larbi A Witkowski JM McElhaney J Loeb M Mitnitski A et al. Aging frailty and age-related diseases. Biogerontology 2010; 11(5): 547-563.

  • [38] Gameiro SR Jammeh ML Wattenberg MM Tsang KY Ferrone S Hodge JW. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure resulting in enhanced T-cell killing. Oncotarget 2014; 5(2): 403-416.

  • [39] Gardner D Jeffery LE Sansom DM. Understanding the CD28/CTLA-4 (CD152) pathway and its implications for costimulatory blockade. Am J Transplant 2014; 14(9): 1985-1991.

  • [40] Gialeli C Theocharis AD Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278(1): 16-27.

  • [41] Gounari M Ntoufa S Apollonio B Papakonstantinou N Ponzoni M Chu CC et al. Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8. Blood 2015; 125(23): 3580-3587.

  • [42] Grabinska K Pelak M Wydmanski J Tukiendorf A d’Amico A. Pr ognost ic val ue and cl inical correlations of 18-fluorodeoxyglucose metabolism quantifiers in gastric cancer. World J Gastroenterol 2015; 21(19): 5901-5909.

  • [43] Gryzik M Grzywocz Z Wasilewska D Kawiak J Stachowiak R Bielecki J et al. Human lymphocytic B-leukemia cell line treatment with the bacterial toxin listeriolysin O and rituximab (anti-CD20 antibody): Effects of similar localization of their receptors. Int J Immunopathol Pharmacol 2015; 28(3): 329-340.

  • [44] Hanagiri T Shigematsu Y Shinohara S Takenaka M Oka S Chikaishi Y et al. Clinical significance of the frequency of regulatory T cells in regional lymph node lymphocytes as a prognostic factor for non-small-cell lung cancer. Lung Cancer 2013; 81(3): 475-479.

  • [45] Harder T Guttek K Philipsen L Simeoni L Schraven B Reinhold D. Selective targeting of transforming growth factor-beta1 into TCR/CD28 signalling plasma membrane domains silences T cell activation. Cell Commun Signal 2014; 12: 74.

  • [46] Hassan SB Sorensen JF Olsen BN Pedersen AE. Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. Immunopharmacol Immunotoxicol 2014; 36(2): 96-104.

  • [47] Hodi FS O’Day SJ McDermott DF Weber RW Sosman JA Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8): 711-723.

  • [48] Hoser G Domagala-Kulaw ik J Droszcz P Droszcz W Kawiak J. Lymphocyte subsets differences in smokers and nonsmokers with primary lung cancer: a flow cytometry analysis of bronchoalveolar lavage fluid cells. Med Sci Monit 2003; 9(8): BR310-BR315.

  • [49] Hoser G Kawiak J. A trypsin inhibitor isolated from lymphatic leukemia cells. Biomed Biochim Acta 1986; 45(9): 1127-1133.

  • [50] Hoser G Kawiak J Domagala-Kulawik J Kopinski P Droszcz W. Flow cytometric evaluation of lymphocyte subpopulations in BALF of healthy smokers and nonsmokers. Folia Histochem Cytobiol 1999; 37(1): 25-30.

  • [51] Hoser G Majsterek I Romana DL Slupianek A Blasiak J Skorski T. Fusion oncogenic t yr osine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance? Leuk Res 2003; 27(3): 267-273.

  • [52] Hoser G Wasilewska D Domagala-Kulawik J. Expression of Fas receptor on peripheral blood lymphocytes from patients with non-small cell lung cancer. Folia Histochem Cytobiol 2004; 42(4): 249-252.

  • [53] Howington JA Blum MG Chang AC Balekian AA Murthy SC. Treatment of stage I and II nonsmall cell lung cancer: Diagnosis and management of lung cancer 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143(5 Suppl): e278S-e313S.

  • [54] Huang G Nishimoto K Yang Y Kleinerman ES. Part icipat ion of t he Fas/FasL signal ing pat hway and the lung microenvironment in the development of osteosarcoma lung metastases. Adv Exp Med Biol 2014; 804: 203-217.

  • [55] Hus I Kawiak J Hoser G Tabarkiewicz J Radej S Dmoszynska A et al. SCID mice model in vivo evaluation of autologous and allogeneic dendritic cells activity on B-cell chronic lymphocytic leukemia. Folia Histochem Cytobiol 2009; 47(4): 563-570.

  • [56] Hus I Schmitt M Tabarkiewicz J Radej S Wojas K Bojarska-Junak A et al. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response. Leukemia 2008; 22(5): 1007-1017.

  • [57] Hutchinson RA Adams RA McArt DG Salto-Tellez M Jasani B Hamilton PW. Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. J Transl Med 2015; 13: 217.

  • [58] Jett JR Schild SE Kesler KA Kalemkerian GP. Tr eatment of small cell lung cancer: Diagnosis and management of lung cancer 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143(5 Suppl): e400S-e419S.

  • [59] Jewett A Tseng HC. Tumor induced inactivation of natural killer cell cytotoxic function; implication in growth expansion and differentiation of cancer stem cells. J Cancer 2011; 2:443-457.

  • [60] Kalia M. Biomarkers for personalized oncology: recent advances and future challenges. Metabolism 2015; 64(3 Suppl 1): S16-S21.

  • [61] Karanikas V Speletas M Zamanakou M Kalala F Loules G Kerenidi T et al. Foxp3 expression in human cancer cells. J Transl Med 2008; 6: 19.

  • [62] Kasprzyk M Slawinski G Musik M Marciniak L Dyszkiewicz W Piwkowski C et al. Completion pneumonectomy and chemoradiotherapy as treatment options in local recurrence of non-small-cell lung cancer. Kardiochir Torakochirurgia Pol 2015; 12(1): 18-25.

  • [63] Kawalec M Skorski T Hoser G. Immunogenicity of cyclophosphamide-treated tumor cells. Arch Immunol Ther Exp (Warsz ) 1988; 36(3): 345-350.

  • [64] Kawiak J Hoser G Malendowicz LK Miks B Skurzak H. Thymocyte and splenocyte subpopulations in normal and leukemia-bearing mice after adrenalectomy. Folia Histochem Cytobiol 1996; 34(2): 75-78.

  • [65] Kawiak J Hoser G Miks B Pojda Z Sobiczewska A Machaj E et al. Populations of thymocytes and peripheral blood leucocytes in leukaemia-bearing mice treated with G-CSF. Immunol Cell Biol 1996; 74(2): 163-166.

  • [66] Kawiak J Hoser G Skorski T. Apoptosis and some of its medical implications. Folia Histochem Cytobiol 1998; 36(3): 99-110.

  • [67] Kawiak J Kawalec M. Leukemia L 1210 cells induce depletion of Lyt 2+ thymocytes. Folia Histochem Cytobiol 1990; 28(1-2): 15-17.

  • [68] Kawiak J Kawalec M Hoser G Miks B Skorski T Pojda Z et al. Changes of t hymocyt e subpopulations induced by activities diffusing from leukemia L1210 cells. Thymus 1991; 18(3):185-192.

  • [69] Kessenbrock K Plaks V Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141(1): 52-67.

  • [70] Kim TH Leslie P Zhang Y. Ribosomal proteins as unrevealed caretakers for cellular stress and genomic instability. Oncotarget 2014; 5(4): 860-871.

  • [71] Kosmaczewska A Bocko D Ciszak L Wlodarska-Polinska I Kornafel J Szteblich A et al. Dysregulated expression of both the costimulatory CD28 and inhibitory CTLA-4 molecules in PB T cells of advanced cervical cancer patients suggests systemic immunosuppression related to disease progression. Pathol Oncol Res 2012; 18(2): 479-489.

  • [72] Kovacsovics-Bankowski M Chisholm L Vercellini J Tucker CG Montler R Haley D et al. Detailed characterization of tumor infiltrating lymphocytes in two distinct human solid malignancies show phenotypic similarities. J Immunother Cancer 2014; 2(1): 38.

  • [73] Krummel MF Allison JP. Pillars article: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. The journal of experimental medicine. 1995. 182: 459-465. J Immunol 2011; 187(7): 3459-3465.

  • [74] Krysko DV Agostinis P Krysko O Garg AD Bachert C Lambrecht BN et al. Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol 2011; 32(4): 157-164.

  • [75] Kyi C Postow MA. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett 2014; 588(2): 368-376.

  • [76] Leick M Catusse J Follo M Nibbs RJ Hartmann TN Veelken H et al. CCL19 is a specific ligand of the constitutively recycling atypical human chemokine receptor CRAM-B. Immunology 2010; 129(4): 536-546.

  • [77] Lin X Chen M Liu Y Guo Z He X Brand D et al. Advances in distinguishing natural from induced Foxp3(+) regulatory T cells. Int J Clin Exp Pathol 2013; 6(2): 116-123.

  • [78] Lindeman NI Cagle PT Beasley MB Chitale DA Dacic S Giaccone G et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists International Association for the Study of Lung Cancer and Association for Molecular Pathology. J Thorac Oncol 2013; 8(7): 823-859.

  • [79] Liu J Fukunaga-Kalabis M Li L Herlyn M. Developmental pathways activated in melanocytes and melanoma. Arch Biochem Biophys 2014; 563: 13-21.

  • [80] Liu L Ge D Ma L Mei J Liu S Zhang Q et al. Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer. J Thorac Oncol 2012; 7(7): 1091-1100.

  • [81] Lugowska I Kowalska M Fuksiewicz M Kotowicz B Mierzejewska E Kosela-Paterczyk H et al. Serum markers in early-stage and locally advanced melanoma. Tumour Biol 2015; 36(11): 8277-85.

  • [82] Ma J Liu L Che G Yu N Dai F You Z. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 2010; 10: 112.

  • [83] Majsterek I Blasiak J Mlynarski W Hoser G Skorski T. Does the bcr/abl-mediated increase in the efficacy of DNA repair play a role in the drug resistance of cancer cells? Cell Biol Int 2002; 26(4): 363-370.

  • [84] Majsterek I Slupianek A Hoser G Skorski T Blasiak J. ABL-fusion oncoproteins activate multi- pathway of DNA repair: role in drug resistance? Biochimie 2004; 86(1): 53-65.

  • [85] Mantovani A Sozzani S Locati M Allavena P Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23(11): 549-555.

  • [86] McCaig AM Cosimo E Leach MT Michie AM. Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12. PLoS One 2012; 7(11): e48929.

  • [87] McCarthy BA Boyle E Wang XP Guzowski D Paul S Catera R et al. Surface expression of Bcl-2 in chronic lymphocytic leukemia and other B-cell leukemias and lymphomas without a breakpoint t(14;18). Mol Med 2008; 14(9-10): 618-627.

  • [88] McDonnell AM Lesterhuis WJ Khong A Nowak AK Lake RA Currie AJ et al. Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens but is reversed by chemotherapy. Eur J Immunol 2015; 45(1): 49-59.

  • [89] Mellstedt H Vansteenkiste J Thatcher N. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience. Lung Cancer 2011; 73(1): 11-17.

  • [90] Mellstedt H Vansteenkiste J Thatcher N. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience. Lung Cancer 2011; 73(1): 11-17.

  • [91] Milpied P Nadel B Roulland S. Pr emalignant cell dynamics in indolent B-cell malignancies. Curr Opin Hematol 2015; 22(4): 388-396.

  • [92] Mimura K Shiraishi K Mueller A Izawa S Kua LF So J et al. The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. J Immunol 2013; 191(12): 6261-6272.

  • [93] Mintern JD Macri C Chin WJ Panozza SE Segura E Patterson NL et al. Differential use of autophagy by primary dendritic cells specialized in cross-presentation. Autophagy 2015; 11(6): 906-917.

  • [94] Mlnarczuk I Mroz P Hoser G Nowis D Bialy LP Ziemba H et al. AAF-cmk sensitizes tumor cells to trail-mediated apoptosis. Leuk Res 2004; 28(1): 53-61.

  • [95] Murdoch C Giannoudis A Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004; 104(8): 2224-2234.

  • [96] Nagasawa T. CXCL12/SDF-1 and CXCR4. Front Immunol 2015; 6:301.

  • [97] Nazzal D Gradolatto A Truffault F Bismuth J Berrih-Aknin S. Human thymus medullary epithelial cells promote regulatory T-cell generation by stimulating interleukin-2 production via ICOS ligand. Cell Death Dis 2014; 5: e1420.

  • [98] Nieborowska-Skorska M Bialek AP Nicolaides NC Iozzo RV Kawalec M Calabretta B et al. The influence of phosphorothioate oligodeoxynucleotides on various organs in vivo. Folia Histochem Cytobiol 1996; 34(2): 69-73.

  • [99] Nieborowska-Skorska M Hoser G Kossev P Wasik MA Skorski T. Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. Blood 2002; 99(12): 4531-4539.

  • [100] Nieborowska-Skorska M Kopinski PK Ray R Hoser G Ngaba D Flis S et al. Rac2-MRC-cIII- generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood 2012; 119(18): 4253-4263.

  • [101] Owen CJ Stewart DA. Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective. Ther Adv Hematol 2015; 6(4): 161-170.

  • [102] Palucka K Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12(4): 265-277.

  • [103] Palucka K Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39(1): 38-48.

  • [104] Petersen RP Campa MJ Sperlazza J Conlon D Joshi MB Harpole DH Jr. et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006; 107(12): 2866-2872.

  • [105] Pizzurro GA Tapia IJ Sganga L Podhajcer OL Mordoh J Barrio MM. Cyt okine-enhanced mat - uration and migration to the lymph nodes of a human dying melanoma cell-loaded dendritic cell vaccine. Cancer Immunol Immunother 2015; 64(11): 1393-1406.

  • [106] Popovic R Shah MY Licht JD. Epigenetic therapy of hematological malignancies: where are we now? Ther Adv Hematol 2013; 4(2): 81-91.

  • [107] Quante M Tu SP Tomita H Gonda T Wang SS Takashi S et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011; 19(2): 257-272.

  • [108] Quatromoni JG Suzuki E Okusanya O Judy BF Bhojnagarwala P Venegas O et al. The timing of TGF-beta inhibition affects the generation of antigen-specific CD8+ T cells. BMC Immunol 2013; 14: 30.

  • [109] Radej S Rolinski J Rawicz-Pruszynski K Bury P Borowski G Furmaga J et al. Immunomodelling Characteristics of Mature Dendritic Cells Stimulated by Colon Cancer Cells Lysates. Pol Przegl Chir 2015; 87(2): 71-82.

  • [110] Radojcic V Bezak KB Skarica M Pletneva MA Yoshimura K Schulick RD et al. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol Immunother 2010; 59(1): 137-148.

  • [111] Ren YR Jin YD Zhang ZH Li L Wu P. Rituximab treatment strategy for patients with diffuse large B-cell lymphoma after first-line therapy: a systematic review and meta-analysis. Chin Med J (Engl ) 2015; 128(3): 378-383.

  • [112] Rivenbark AG Stolzenburg S Beltran AS Yuan X Rots MG Strahl BD et al. Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics 2012; 7(4): 350-360.

  • [113] Robak P Smolewski P Robak T. Emerging immunological drugs for chronic lymphocytic leukemia. Expert Opin Emerg Drugs 2015; 20(3): 423-447.

  • [114] Rycaj K Tang DG. Cell-of-Origin of Cancer versus Cancer Stem Cells: Assays and Interpretations. Cancer Res 2015; 75(19): 4003-4011.

  • [115] Sabbatini P Tsuji T Ferran L Ritter E Sedrak C Tuballes K et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res 2012; 18(23): 6497-6508.

  • [116] Salmon H Franciszkiewicz K Damotte D Dieu-Nosjean MC Validire P Trautmann A et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest 2012; 122(3): 899-910.

  • [117] Sanmamed MF Pastor F Rodriguez A Perez-Gracia JL Rodriguez-Ruiz ME Jure-Kunkel M et al. Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137 OX40 GITR CD27 CD28 and ICOS. Semin Oncol 2015; 42(4): 640-655.

  • [118] Schmitt EG Williams CB. Generation and function of induced regulatory T cells. Front Immunol 2013; 4: 152.

  • [119] Schneider H Rudd CE. Diverse mechanisms regulate the surface expression of immunotherapeutic target ctla-4. Front Immunol 2014; 5: 619.

  • [120] Shekarian T Valsesia-Wittmann S Caux C Marabelle A. Paradigm shift in oncology: targeting the immune system rather than cancer cells. Mutagenesis 2015; 30(2): 205-211.

  • [121] Shen X Zheng JY Shi H Zhang Z Wang WZ. Survivin knockdown enhances gastric cancer cell sensitivity to radiation and chemotherapy in vitro and in nude mice. Am J Med Sci 2012; 344(1): 52-58.

  • [122] Shibata T. Current and future molecular profiling of cancer by next-generation sequencing. Jpn J Clin Oncol 2015; 45(10): 895-899.

  • [123] Skirecki T Hoser G Kawiak J Dziedzic D Domagala-Kulawik J. Flow cytometric analysis of C. Arch Immunol Ther Exp (Warsz ) 2014; 62(1): 67-75.

  • [124] Skorski T Nieborowska-Skorska M Wlodarski P Perrotti D Hoser G Kawiak J et al. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides. J Natl Cancer Inst 1997; 89(2): 124-133.

  • [125] Slupianek A Hoser G Majsterek I Bronisz A Malecki M Blasiak J et al. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair prolongation of G(2)/M phase and protection from apoptosis. Mol Cell Biol 2002; 22(12): 4189-4201.

  • [126] Smeets RL Fleuren WW He X Vink PM Wijnands F Gorecka M et al. Molecular pathway profiling of T lymphocyte signal transduction pathways; Th1 and Th2 genomic fingerprints are defined by TCR and CD28-mediated signaling. BMC Immunol 2012; 13: 12.

  • [127] Smigielski J Piskorz L Talar-Wojnarowska R Malecka-Panas E Jablonski S Brocki M. The estimation of metaloproteinases and their inhibitors blood levels in patients with pancreatic tumors. World J Surg Oncol 2013; 11: 137.

  • [128] Smolej L. Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab. Pharmgenomics Pers Med 2015; 8: 1-7.

  • [129] Spranger S Spaapen RM Zha Y Williams J Meng Y Ha TT et al. Up-regulation of PD-L1 IDO and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013; 5(200): 200ra116.

  • [130] Srivastava MK Andersson A Zhu L Harris-White M Lee JM Dubinett S et al. Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy 2012; 4(3): 291-304.

  • [131] Srivastava MK Dubinett S Sharma S. Targeting MDSCs enhance therapeutic vaccination responses against lung cancer. Oncoimmunology 2012; 1(9):1650-1651.

  • [132] Srivastava MK Zhu L Harris-White M Kar UK Huang M Johnson MF et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One 2012; 7(7): e40677.

  • [133] Stachowiak R Lyzniak M Grabowska M Roeske K Jagielski T Bielecki J et al. Cytotoxicity of purified listeriolysin O on mouse and human leukocytes and leukaemia cells. BMC Biotechnol 2014; 14: 77.

  • [134] Sundar R Soong R Cho BC Brahmer JR Soo RA. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014; 85(2): 101-109.

  • [135] Tanaka T Okuya K Kutomi G Takaya A Kajiwara T Kanaseki T et al. Heat shock protein 90 targets a chaperoned peptide to the static early endosome for efficient cross-presentation by human dendritic cells. Cancer Sci 2015; 106(1): 18-24.

  • [136] Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res 2012; 22(3): 457-472.

  • [137] Tao H Mimura Y Aoe K Kobayashi S Yamamoto H Matsuda E et al. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer 2012; 75(1): 95-101.

  • [138] Tartour E Zitvogel L. Lung cancer: potential targets for immunotherapy. Lancet Respir Med 2013; 1(7): 551-563.

  • [139] Taube JM Anders RA Young GD Xu H Sharma R McMiller TL et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4(127): 127ra37.

  • [140] Ten Hacken E Burger JA. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. Biochim Biophys Acta 2016; 1863(3): 401-13.

  • [141] Teo EC Chew Y Phipps C. A review of monoclonal antibody therapies in lymphoma. Crit Rev Oncol Hematol 2016; 97: 72-84.

  • [142] Tran Janco JM Lamichhane P Karya mpudi L Knutson KL. Tumor-infiltrating dendritic cells in cancer pathogenesis. J Immunol 2015; 194(7): 2985-2991.

  • [143] Traves PG Luque A Hortelano S. Macrophages inflammation and tumor suppressors: ARF a new player in the game. Mediators Inflamm 2012; 2012: 568783.

  • [144] Urso L Calabrese F Favaretto A Conte P Pasello G. Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment. Crit Rev Oncol Hematol 2016;97: 220-30.

  • [145] Vacchelli E Aranda F Eggermont A Galon J Sautes-Fridman C Cremer I et al. Tr ial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2014; 3(1):e27878.

  • [146] Vardi A Agathangelidis A Stalika E Karypidou M Siorenta A Anagnostopoulos A et al. Ant igen Selection Shapes the T-cell Repertoire in Chronic Lymphocytic Leukemia. Clin Cancer Res 2016; 22(1): 167-74.

  • [147] Wade M Li YC Wahl GM. MDM2 MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013; 13(2) :83-96.

  • [148] Walker LS Sansom DM. Confusing signals: recent progress in CTLA-4 biology. Trends Immunol 2015; 36(2): 63-70.

  • [149] Wei S Wang H Lu C Malmut S Zhang J Ren S et al. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins. J Biol Chem 2014; 289(13): 8947-8959.

  • [150] Wlodarski P Wasik M Ratajczak MZ Sevignani C Hoser G Kawiak J et al. Role of p53 in hematopoietic recovery after cytotoxic treatment. Blood 1998; 91(8): 2998-3006.

  • [151] Wlodkowic D Skommer J Darzynkiewicz Z. Cytometry of apoptosis. Historical perspective and new advances. Exp Oncol 2012; 34(3): 255-262.

  • [152] Yan W Herman JG Guo M. Epigenome-based personalized medicine in human cancer. Epigenomics 2016; 8(1): 119-33.

  • [153] Yao S Zhu Y Chen L. Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov 2013; 12(2): 130-146.

  • [154] Yonezawa S Higashi M Yamada N Yokoyama S Kitamoto S Kitajima S et al. Mucins in human neoplasms: clinical pathology gene expression and diagnostic application. Pathol Int 2011; 61(12): 697-716.

  • [155] Zanardelli M Micheli L Nicolai R Failli P Ghelardini C Di Cesare ML. Different apoptotic pathways activated by oxaliplatin in primary astrocytes vs. colo-rectal cancer cells. Int J Mol Sci 2015; 16(3): 5386-5399.

  • [156] Zolnierowicz J Ambrozek-Latecka M Kawiak J Wasilewska D Hoser G. Monitoring cell proliferation in vitro with different cellular fluorescent dyes. Folia Histochem Cytobiol 2013; 51(3): 193-200.

  • [157] Zou Q Wu B Xue J Fan X Feng C Geng S et al. CD8+ Treg cells suppress CD8+ T cell-responses by IL-10-dependent mechanism during H5N1 influenza virus infection. Eur J Immunol 2014; 44(1): 103-114.

Search
Journal information
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 436 213 4
PDF Downloads 150 96 4